Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads
- PDF / 4,336,292 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 102 Downloads / 228 Views
Open Access
CORRECTION
Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia Jessica M. Salmon1,5, Michael Bots2, Eva Vidacs1, Kym L. Stanley1, Peter Atadja3, Johannes Zuber4 and Ricky W. Johnstone1,5*
Correction to: Clinical Epigenetics (2015) 7:2, https://doi.org/10.1186/s13148-014-0034-4
Following publication of the original article [1], the authors identified an error in Fig. 2e. The correct Fig. 2 is given below.
The original article can be found online at https://doi.org/10.1186/s1314 8-014-0034-4. *Correspondence: [email protected] 1 Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC 3002, Australia Full list of author information is available at the end of the article © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
30
60 40
*
20 0
*
% GFP (BM)
% GFP (BM)
80
b
Sca1
**
20
10
*
10
0
-
+
+
pan.
-
+
+
ATO
-
-
+
ATO
-
-
+
20 10 0
10
PI
PI
10
+
+
pan.
-
+
+
ATO
-
-
+
ATO
-
-
+
4 3 2 1
ATO
e
H&E
TUNEL
1
0
10
4
-
+ vehicle
+
1 10
2 3 10 10 Annexin V (APC)
10
4
Q1 1.02
2
1
0
Q4 87.9 0 10
10
10
1
0
10
10 Q3 3.21 1 10
2 3 10 10 Annexin V (APC)
Q3 4.69 1 10
2 3 10 10 Annexin V (APC)
4 10
pan.+ ATO Q2 19.7
Q4 64.8
Q2 6.43
3
4 10
2
10
4
Q1 4.28
Q2 50.2
3
2
1
0
4 10
Q4 40.4 0 10
Q3 5.12 1 10
2 3 10 10 Annexin V (APC)
4 10
Annexin V
2.0
*
1.5 1.0 0.5
pan. ATO
panobinostat
Q3 4.31
Q1 12.3
0.0
+ +
10
10 Q4 88.7
3
d
5
10
10
2
Relative TUNEL +ve staining /cell area
Normalised Annexin +ve
c
pan. Q2 6.28
3
0 10
-
0
10
10
pan.
pan.
Q1 0.70
ATO 10
20
4
0 10
*
30
0
10
Gr1
40
*
30
% GFP (BM)
% GFP (BM)
40
10
10
pan.
Mac1
vehicle 10
PI
c-Kit
Page 2 of 3
PI
a
(2020) 12:178
PI
Salmon et al. Clin Epigenet
ATO
+ -
+
+ + pan. + ATO
Salmon et al.
Data Loading...
